A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

NCT03003676 | Completed Phase 1 Results

• 1 other identifier: ONCOS C824
• Study Type: interventional
• Target: 21
• Locations: 2 countries
• Sites: 4

Brief Summary

This is a multi center, phase I pilot study of sequential ONCOS-102 and pembrolizumab in patients with advanced or unresectable melanoma progressing after PD1 blockade. The primary objective of the study is to determine the safety of sequential treatment with ONCOS-102 followed by pembrolizumab. The protocol aims to enroll patients into two cohorts: Part I: up to 12 patients will receive sequential treatment with ONCOS-102 followed by pembrolizumab. Part II: up to 12 patients will receive an initial treatment phase with ONCOS-102 followed by a treatment phase with ONCOS-102 in combination with pembrolizumab.

Conditions

Advanced or Unresectable Melanoma Progressing After PD1 Blockade

Outcome Measures

Primary Outcomes (1)

• Incidence of Treatment-emergent Adverse Events Including Treatment-emergent Serious Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE).

  6 months

Secondary Outcomes (8)

• Objective Response Rates by RECIST 1.1 and irRECIST.

  6 months

• Changes in Immune Cell Subsets in Tumor Tissue Before and After ONCOS-102 and Pembrolizumab.

  6 months

• Changes in Immune Cell Subsets in Peripheral Blood Before and After ONCOS-102 and Pembrolizumab.

  6 months

• Correlation of Tumour Infiltrating Lymphocytes (TILs) and Overall Response Rate (ORR).

  6 months

• Progression Free Survival (PFS) Assessed by RECIST 1.1 and irRECIST.

  6 months

Other Outcomes (3)

• Somatic Mutational Rate and Neoepitope Burden in Tumors and Explore Relationship to Response.

  6 months

• Changes in T Cell Receptor Clonality in Infiltrating and Circulating T Cells.

  6 months

• Gene Expression Changes in the Tumor Microenvironment and Peripheral Blood.

  6 months

Study Arms (1)

Experimental: ONCOS-102+cyclophosphamide+pembrolizumab

EXPERIMENTAL

Part I: Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x10\^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24). Part II: Patients will receive 4 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, 8 and 15) at 3x10\^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. ONCOS-102 will be given in combination with Pembrolizumab starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity or clinically relevant disease progression, whichever occurs first. Pembrolizumab will be given according to institutional practice (2mg/kg or 200mg flat dose).

Biological: ONCOS-102; Drug: Cyclophosphamide; Drug: Pembrolizumab

Interventions

ONCOS-102 BIOLOGICAL

Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)

Experimental: ONCOS-102+cyclophosphamide+pembrolizumab

Cyclophosphamide DRUG

Pre-treatment

Experimental: ONCOS-102+cyclophosphamide+pembrolizumab

Pembrolizumab DRUG

PD1 blockade

Experimental: ONCOS-102+cyclophosphamide+pembrolizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults 18 years of age or older.
• For US sites: Histopathologically confirmed melanoma with an injectable cutaneous or lymph node metastasis that has progressed in the opinion of the treating investigator despite administering a Food and Drug Administration (FDA) approved anti-PD1 agent, with or without ipilimumab.
• For European sites: Histopathologically confirmed melanoma with an injectable cutaneous or lymph node metastasis that has progressed in the opinion of the treating investigator despite administering a regulatory approved anti-PD1 agent, with or without ipilimumab.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
• Measurable disease according to RECIST 1.1.
• Acceptable coagulation status: international normalised ratio (INR) of blood clotting, prothrombin time and activated partial thromboplastin time within ≤1.5 x upper limit of normal (ULN).
• Completion of local therapy, such as radiation, surgical resection, injectable immunebased therapy, or topical pro-inflammatory agent, 21 days prior to first dose of protocol therapy.
• Adverse events from previous cancer therapies (excluding alopecia) must have recovered to grade 1 (CTCAE, most recent version). Stable grade 2 AEs such as endocrine conditions are allowed, and other chronic stable AEs may be considered on a case by case basis by the Principal Investigator.
• Clinical stability of brain metastases for at least 4 weeks prior to first day of study therapy.
• Acceptable liver and renal functions defined as:
• Total bilirubin ≤1.5 x ULN (does not include patients with Gilbert's Disease)
• Aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) ≤3.0 x ULN
• Serum creatinine ≤1.5 x ULN
• Acceptable haematological function defined as (Patients can be transfused to meet the haemoglobin entry criteria):
• Haemoglobin ≥9 g/dL

You may not qualify if:

• A concomitant medical condition requiring receipt of a therapeutic anticoagulant that in the opinion of the treating physician cannot safely allow for therapeutic injection of ONCOS-102 and tumor biopsies. Local clinical practice can be followed with regard to holding a therapeutic anticoagulant during invasive procedures such as biopsies.
• A concomitant medical condition that in the opinion of the treating physician would pose unreasonable additional risk to therapeutic injection of ONCOS-102.
• For US sites: Receipt of Investigational agents within 28 days prior to first dose of protocol therapy.
• For European sites: Current participation or participation in a study of an investigational agent within 28 days prior to first dose of protocol therapy. Note: participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
• Any symptomatic autoimmune disease (such as lupus, scleroderma, Crohn's disease, ulcerative colitis) that requires administration of \>10mg of prednisone equivalent. Lower dose steroids for conditions such as hypophysitis are allowed.
• Any prior severe adverse event attributed to prior anti-PD1 therapy that, in the Principal investigator's opinion, would contraindicate pembrolizumab administration such as:
• Grade 2 or higher pneumonitis
• Grade 4 AST or ALT elevation
• Grade 3 or higher colitis attributable to PD1 blockade; note that colitis attributable to ipilimumab is not excluded
• Note: in the absence of clinical symptoms of pancreatitis, elevations of amylase or lipase are not contraindications to therapy on this trial
• Active bacterial, viral, or fungal infections, requiring systemic therapy apart from anti-viral maintenance therapy for HIV.
• History of organ transplant.
• Patients requiring chronic systemic immunosuppressants, including steroids (prednisone daily equivalent of \>10 mg).
• Brain metastases that are clinically unstable (e.g. showing unequivocal growth on imaging, requiring radiation therapy, or steroids \>10mg of prednisone equivalent) within 4 weeks of first dose of study drug.
• Known severe congenital or acquired cellular or humoral immunodeficiency such as common variable immunodeficiency.

Sponsors & Collaborators

• Targovax Oy: lead

Study Sites (4)

University of Maryland Comprehensive Cancer Center

Baltimore, Maryland, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Location

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Location

Oslo University Hospital - The Norwegian Radium Hospital

Oslo, Norway

Location

Related Publications (1)

• Kuryk L, Moller AW, Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2018 Oct 29;8(2):e1532763. doi: 10.1080/2162402X.2018.1532763. eCollection 2019.

  PMID: 30713786 DERIVED

MeSH Terms

Interventions

Cyclophosphamide; pembrolizumab

Intervention Hierarchy (Ancestors)

Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Hydrocarbons; Organic Chemicals; Phosphoramides; Organophosphorus Compounds

Results Point of Contact

• Title: Dr. Lone H. Ottesen, Chief Development Officer
• Organization: Targovax

lone.ottesen@targovax.com

+44 7920567911

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 19, 2016
• First Posted: December 28, 2016
• Study Start: December 1, 2016
• Primary Completion: July 1, 2020
• Study Completion: October 1, 2020
• Last Updated: November 8, 2021
• Results First Posted: August 9, 2021

Record last verified: 2021-07

Locations

NO (1); US (3)